Virus-specific T cells from cryopreserved blood during an emergent virus outbreak for a potential off-the-shelf therapy.

[1]  M. Kamboj,et al.  SARS-CoV-2 in immunocompromised individuals , 2022, Immunity.

[2]  Peter Shaw,et al.  Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant , 2022, Blood advances.

[3]  Christopher A. Lazarski,et al.  Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products , 2022, Molecular Therapy - Methods & Clinical Development.

[4]  M. Hallek,et al.  Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy , 2022, Frontiers in Bioengineering and Biotechnology.

[5]  J. Knight,et al.  SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study , 2022, The Lancet Microbe.

[6]  Katherine K. Matthews,et al.  SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants , 2022, PLoS pathogens.

[7]  Oliver J. Klein,et al.  Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients , 2022, Molecular Therapy - Methods & Clinical Development.

[8]  D. Jekarl,et al.  Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment , 2021, Frontiers in Immunology.

[9]  Simona Baghai Sain,et al.  Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection , 2021, Nature.

[10]  Hongzhou Lu,et al.  Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals , 2021, Cell discovery.

[11]  A. Sette,et al.  Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. , 2021, Blood advances.

[12]  C. Farnsworth,et al.  HLA genetic polymorphism in patients with Coronavirus Disease 2019 in Midwestern United States , 2021, HLA.

[13]  P. Barie,et al.  Virus Induced Lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics , 2021, Scientific Reports.

[14]  Tamara J Laskowski,et al.  Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy , 2021, Cell Reports.

[15]  E. Shin,et al.  SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells , 2021, Nature Communications.

[16]  Gavin J. D. Smith,et al.  Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.

[17]  L. Jarvis,et al.  Rapid GMP-Compliant Expansion of SARS-CoV-2–Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19 , 2021, Frontiers in Immunology.

[18]  M. Turner,et al.  Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV‐specific T cell therapy , 2021, Clinical and experimental immunology.

[19]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[20]  T. Mora,et al.  Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection , 2021, eLife.

[21]  S. Mallal,et al.  Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.

[22]  J. Sibilia,et al.  Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France , 2020, Emerging infectious diseases.

[23]  Christopher A. Lazarski,et al.  SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein , 2020, Blood.

[24]  P. Klenerman,et al.  T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses , 2020, Nature Communications.

[25]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[26]  J. Deelen,et al.  Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19 , 2020, Journal of translational medicine.

[27]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[28]  A. Sette,et al.  Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.

[29]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[30]  M. J. Herrero,et al.  HLA‐A, ‐B, ‐C, ‐DRB1, and ‐DQB1 allele and haplotype frequencies: An analysis of umbilical cord blood units at the Barcelona Cord Blood Bank , 2019, HLA.

[31]  R. Krance,et al.  "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. , 2019, Blood advances.

[32]  A. Doglio,et al.  A comparison of two protocols for optimal red blood cell depletion using Sepax-2 device for ABO-major incompatible transplantation in adults. , 2019, Current research in translational medicine.

[33]  D. Bloom,et al.  Infectious Disease Threats in the Twenty-First Century: Strengthening the Global Response , 2019, Front. Immunol..

[34]  C. Bollard,et al.  Virus-Specific T Cells for the Immunocompromised Patient , 2017, Front. Immunol..

[35]  Mikhail Shugay,et al.  Antigen receptor repertoire profiling from RNA-seq data , 2017, Nature Biotechnology.

[36]  P. Hanley,et al.  A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy , 2016, Scientific Reports.

[37]  Mikhail Shugay,et al.  MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.

[38]  M. Schilham,et al.  Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection , 2010, Haematologica.

[39]  M. Quigley,et al.  CD4 T Cells Are Required for CD8 T Cell Survival during Both Primary and Memory Recall Responses1 , 2007, The Journal of Immunology.

[40]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[41]  S. Mackinnon,et al.  Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.